Tag: Cancer: Rectal
Findings of IDEA Collaboration Have Influenced Prescribing Patterns
Significant increasing trend seen for use of three months of adjuvant chemotherapy for resected stage III colon cancer
GI Symptoms Persist in Most Female Colorectal Cancer Survivors
Most common symptoms include bloating/gas, constipation, diarrhea
Time to Treatment Not Tied to Worse Outcomes in Young Colorectal Cancer Patients
Findings seen for both overall survival and cause-specific survival
People With Mental Disorders Less Likely to Complete CRC Screening
Furthermore, people with mental disorders have higher proportion of positive fecal immunochemical test results than the general population
ACP: Screening Average-Risk Adults for Colorectal Cancer Should Start at 50 Years
For asymptomatic average-risk adults, clinicians should consider not screening at age 45 to 49 years, according to ACP
Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
Significantly improved overall survival seen with fruiquintinib versus placebo, with favorable safety profile
Risk Factors Identified for Early-Onset Sporadic Colorectal Cancer
Independent risk factors include age, body mass index, comorbidity, first- or second-degree relative with CRC, alcohol use
Doubling Up on FIT Testing Catches More Colorectal Cancers
Two-test strategy has sensitivity of 96.6 percent versus 84.1 percent for single-test strategy
Locally Recurrent Rectal Cancer QoL Is Valid Patient-Reported Outcome Measure
LRRC-QoL consisted of nine multi-item scales and three single items; has convergent validity with other measures
ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer
Findings seen in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery
